Global Age Related Macular Degeneration Drug Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Summary

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

According to APO Research, The global Age Related Macular Degeneration Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Age Related Macular Degeneration Drug include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche and Kanghong Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Age Related Macular Degeneration Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Age Related Macular Degeneration Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Age Related Macular Degeneration Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Age Related Macular Degeneration Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Age Related Macular Degeneration Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Age Related Macular Degeneration Drug sales, projected growth trends, production technology, application and end-user industry.

Age Related Macular Degeneration Drug Segment by Company

Regeneron Pharmaceuticals
Bayer HealthCare
Novartis
Roche
Kanghong Pharma

Age Related Macular Degeneration Drug Segment by Type

Lucentis
Eylea
Avastin
Others

Age Related Macular Degeneration Drug Segment by Application

Hospitals
Clinics
Others

Age Related Macular Degeneration Drug Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Age Related Macular Degeneration Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Age Related Macular Degeneration Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Age Related Macular Degeneration Drug Market Size, 2020 VS 2024 VS 2031
1.3 Global Age Related Macular Degeneration Drug Market Size Estimates and Forecasts (2020-2031)
1.4 Global Age Related Macular Degeneration Drug Sales Estimates and Forecasts (2020-2031)
1.5 Global Age Related Macular Degeneration Drug Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Age Related Macular Degeneration Drug Market Dynamics
2.1 Age Related Macular Degeneration Drug Industry Trends
2.2 Age Related Macular Degeneration Drug Industry Drivers
2.3 Age Related Macular Degeneration Drug Industry Opportunities and Challenges
2.4 Age Related Macular Degeneration Drug Industry Restraints
3 Age Related Macular Degeneration Drug Market by Manufacturers
3.1 Global Age Related Macular Degeneration Drug Revenue by Manufacturers (2020-2025)
3.2 Global Age Related Macular Degeneration Drug Sales by Manufacturers (2020-2025)
3.3 Global Age Related Macular Degeneration Drug Average Sales Price by Manufacturers (2020-2025)
3.4 Global Age Related Macular Degeneration Drug Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Age Related Macular Degeneration Drug Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Age Related Macular Degeneration Drug Manufacturers, Product Type & Application
3.7 Global Age Related Macular Degeneration Drug Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Age Related Macular Degeneration Drug Market CR5 and HHI
3.8.2 Global Top 5 and 10 Age Related Macular Degeneration Drug Players Market Share by Revenue in 2024
3.8.3 2024 Age Related Macular Degeneration Drug Tier 1, Tier 2, and Tier 3
4 Age Related Macular Degeneration Drug Market by Type
4.1 Age Related Macular Degeneration Drug Type Introduction
4.1.1 Lucentis
4.1.2 Eylea
4.1.3 Avastin
4.1.4 Others
4.2 Global Age Related Macular Degeneration Drug Sales by Type
4.2.1 Global Age Related Macular Degeneration Drug Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Age Related Macular Degeneration Drug Sales by Type (2020-2031)
4.2.3 Global Age Related Macular Degeneration Drug Sales Market Share by Type (2020-2031)
4.3 Global Age Related Macular Degeneration Drug Revenue by Type
4.3.1 Global Age Related Macular Degeneration Drug Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
4.3.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2020-2031)
5 Age Related Macular Degeneration Drug Market by Application
5.1 Age Related Macular Degeneration Drug Application Introduction
5.1.1 Hospitals
5.1.2 Clinics
5.1.3 Others
5.2 Global Age Related Macular Degeneration Drug Sales by Application
5.2.1 Global Age Related Macular Degeneration Drug Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Age Related Macular Degeneration Drug Sales by Application (2020-2031)
5.2.3 Global Age Related Macular Degeneration Drug Sales Market Share by Application (2020-2031)
5.3 Global Age Related Macular Degeneration Drug Revenue by Application
5.3.1 Global Age Related Macular Degeneration Drug Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
5.3.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2020-2031)
6 Global Age Related Macular Degeneration Drug Sales by Region
6.1 Global Age Related Macular Degeneration Drug Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Age Related Macular Degeneration Drug Sales by Region (2020-2031)
6.2.1 Global Age Related Macular Degeneration Drug Sales by Region (2020-2025)
6.2.2 Global Age Related Macular Degeneration Drug Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Age Related Macular Degeneration Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Age Related Macular Degeneration Drug Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Age Related Macular Degeneration Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Age Related Macular Degeneration Drug Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Age Related Macular Degeneration Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Age Related Macular Degeneration Drug Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Age Related Macular Degeneration Drug Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Age Related Macular Degeneration Drug Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Age Related Macular Degeneration Drug Revenue by Region
7.1 Global Age Related Macular Degeneration Drug Revenue by Region
7.1.1 Global Age Related Macular Degeneration Drug Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Age Related Macular Degeneration Drug Revenue by Region (2020-2025)
7.1.3 Global Age Related Macular Degeneration Drug Revenue by Region (2026-2031)
7.1.4 Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Age Related Macular Degeneration Drug Revenue (2020-2031)
7.2.2 North America Age Related Macular Degeneration Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Age Related Macular Degeneration Drug Revenue (2020-2031)
7.3.2 Europe Age Related Macular Degeneration Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Age Related Macular Degeneration Drug Revenue (2020-2031)
7.4.2 Asia-Pacific Age Related Macular Degeneration Drug Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Age Related Macular Degeneration Drug Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Age Related Macular Degeneration Drug Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Regeneron Pharmaceuticals
8.1.1 Regeneron Pharmaceuticals Comapny Information
8.1.2 Regeneron Pharmaceuticals Business Overview
8.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
8.1.5 Regeneron Pharmaceuticals Recent Developments
8.2 Bayer HealthCare
8.2.1 Bayer HealthCare Comapny Information
8.2.2 Bayer HealthCare Business Overview
8.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
8.2.5 Bayer HealthCare Recent Developments
8.3 Novartis
8.3.1 Novartis Comapny Information
8.3.2 Novartis Business Overview
8.3.3 Novartis Age Related Macular Degeneration Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
8.3.5 Novartis Recent Developments
8.4 Roche
8.4.1 Roche Comapny Information
8.4.2 Roche Business Overview
8.4.3 Roche Age Related Macular Degeneration Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
8.4.5 Roche Recent Developments
8.5 Kanghong Pharma
8.5.1 Kanghong Pharma Comapny Information
8.5.2 Kanghong Pharma Business Overview
8.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
8.5.5 Kanghong Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Age Related Macular Degeneration Drug Value Chain Analysis
9.1.1 Age Related Macular Degeneration Drug Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Age Related Macular Degeneration Drug Production Mode & Process
9.2 Age Related Macular Degeneration Drug Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Age Related Macular Degeneration Drug Distributors
9.2.3 Age Related Macular Degeneration Drug Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings